Original Research Article

Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein

Muhammad S. Khan¹,², Eun Kim¹, Alex McPherson²,³, Florian J. Weisel³, Shaohua Huang¹, Thomas W. Kenniston¹, Elena Percivalle⁴, Irene Cassaniti⁴, Fausto Baldanti⁴,⁵, Marlies Meisel³ and Andrea Gambotto¹,²,⁶,⁷,⁸,*

¹Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA, ²Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA, ³Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15260, USA, ⁴Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy, ⁵Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy, ⁶UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA, ⁷Division of Infectious Disease, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA, and ⁸Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Received: May 24, 2022; Revised: June 27, 2022; Accepted: July 4, 2022

ABSTRACT

Additional COVID-19 vaccines that are safe and immunogenic are needed for global vaccine equity. Here, we developed a recombinant type 5 adenovirus vector encoding for the SARS-CoV-2 S1 subunit antigen and nucleocapsid as a fusion protein (Ad5.SARS-CoV-2-S1N). A single subcutaneous immunization with Ad5.SARS-CoV-2-S1N induced a similar humoral response, along with a significantly higher S1-specific cellular response, as a recombinant type 5 adenovirus vector encoding for S1 alone (Ad5.SARS-CoV-2-S1). Immunogenicity was improved by homologous prime-boost vaccination, and further improved through intramuscular heterologous prime-boost vaccination using subunit recombinant S1 protein. Priming with low dose (1 × 10¹⁰ v.p.) of Ad5.SARS-CoV-2-S1N and boosting with either wild-type recombinant rS1 or B.1.351 recombinant rS1 induced a robust neutralizing response, which was sustained against Beta and Gamma SARS-CoV-2 variants. This novel Ad5-vectored SARS-CoV-2 vaccine candidate showed promising immunogenicity in mice and supports the further development of COVID-19-based vaccines incorporating the nucleoprotein as a target antigen.

Statement of Significance: Investigation of SARS-CoV-2 vaccines targeting antigens outside of spike is a point of interest for next-generation SARS-CoV-2 vaccines due to the emergence of immune evasive SARS-CoV-2 variants. This work represents the first published investigation of a spike and nucleoprotein fusion vaccine antigen.

KEYWORDS: recombinant DNA vaccines; adenovirus; infectious diseases; SARS-CoV-2; COVID-19

INTRODUCTION

The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to have a large impact on public health across the globe [1–3]. COVID-19 first emerged in 2019, was declared a global pandemic by the World Health Organization on 11 March 2020, and has since claimed approximately 5.6 million lives as of 24 January 2022. Vaccination continues to be one of the most effective public health interventions to curb infectious diseases and their impact on human, and animal,
Antibody Therapeutics, 2022

Global vaccine inequality has, and will continue to, lead to new SARS-CoV-2 variants.

Beta coronaviruses (BetaCoVs), such as SARS-CoV-2, are enveloped, positive sense, ssRNA viruses [22, 23]. BetaCoVs encode the envelope, nucleocapsid (N), membrane, and spike (S) proteins [24, 25]. The spike protein has been the focus of currently approved COVID-19 vaccines, and of various COVID-19 vaccines in development, due to its role in viral infection of host cells [26]. The S protein composed of two subunits, S1 and S2, that allow for viral attachment to the host cell receptor and in fusion to the host cellular membrane [26, 27]. It has been demonstrated that antibodies targeting the S protein can block the binding of SARS-CoV-2 to the cell receptor, allowing the S protein to be a focal target of vaccine development [28–32]. Our previously published reports on vaccines against not only SARS-CoV-2, but also SARS-CoV-1 and MERS, have shown the ability of S1 subunit targeting vaccines to generate neutralizing antibody response [33–36]. Our previous efforts have established the immunogenicity of S1-based BetaCoVs vaccines through both Adenoviral (Ad)-vectored vaccines and subunit recombinant protein vaccines. Most recently, we have described an Ad-vectored SARS-CoV-2 vaccine expressing S1 alone generating a robust immune response in BALB/cJ mice [34]. We have also presented skin-targeted S1 subunit protein vaccines that induce antigen-specific antibody responses against MERS-CoV and SARS-CoV-2 [33].

Of particular interest is the investigation of including more conserved regions of SARS-CoV-2, such as the N protein, in vaccine strategies to combat emerging variants. The primary function of the SARS-CoV-2 N protein is to package the viral genome [37]. The N protein is more conserved than the S protein, with 90% amino acid homology, and also accumulates fewer mutations over time [38, 39]. The N protein also contains key T-cell epitopes for SARS-CoV-2 immunity [40–42]. The literature suggests potential for an S1- and N-based COVID-19 vaccine that incorporates the neutralizing antibody response to S1 with the conserved T-cell response to N. One concern with including other SARS-CoV-2 proteins, outside of S, is that it will reduce the S-specific antibody response and reduce the neutralizing antibody response against SARS-CoV-2. This manuscript thoroughly investigates the impact of including N, as a S1N fusion antigen, on S1-specific antibody response, S1-specific IgG isotype switch, and neutralization response against live SARS-CoV-2, adding crucial information for next-generation SARS-CoV-2 vaccines.

Adenovirus (Ad)-vectored vaccines have been investigated thoroughly due to their ability to induce a balanced humoral and cellular immune response [43–45]. Our previous studies using Ad-vectored vaccines expressing SARS-CoV-2-S1, SARS-CoV-1-S1, and MERS-S1 have illustrated the potential for Ad-based vaccines against coronavirus diseases. Indeed, there have been a number of Ad-based SARS-CoV-2 (including Ad5, Ad26, and chimpanzee adenovirus vectors) vaccines that have shown promising results in clinical trials [46]. The Ad5-vectored COVID-19 vaccine, CanSino Convidicea Vaccine (Ad5-nCoV), encoding for the full S protein has also shown promising immunogenicity when delivered intramuscularly and has been approved by multiple countries [47–49]. Although there has been remarkable progress of Ad-based COVID-19 vaccines, there is still a need for investigation of novel vaccine strategies, such as including the N protein, or homologous and heterologous prime-boost strategies, which induce sustained immunity against SARS-CoV-2 variants.

Here, we describe the development of multiple Ad-vectored and subunit recombinant protein SARS-CoV-2 vaccine candidates against COVID-19. We designed and constructed a recombinant type 5 Ad vector encoding for a fusion protein S1N subunit antigen (Ad5.SARS-CoV-2-S1N). We evaluated the immunogenicity of a single immunization, along with homologous and heterologous prime-boost immunization, of this vaccine in BALB/cJ mice through multiple delivery routes including intranasal (I.N.) delivery, subcutaneous (S.C.) injection, and intramuscular (I.M.) injection. We investigated the ability of Ad5.SARS-CoV-2-S1N to induce antigen-specific humoral and cellular immune responses and investigated the virus-specific neutralization activity of the generated antibodies. Our study demonstrates the development of an Ad-based SARS-CoV-2 vaccine, along with heterologous boost using subunit recombinant SARS-CoV-2 vaccine, that can induce robust and durable SARS-CoV-2 specific immune response in mice, which is sustained against Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variants.

RESULTS

Adenoviral SARS-CoV-2 S1N vaccine

To produce E1/E3 deleted replication-deficient human type 5 adenovirus expressing SARS-CoV-2-S1 protein, we generated pAd/SARS-CoV-2-S1N by subcloning the codon-optimized SARS-CoV-2-S1 and wild-type Nucleoprotein gene into the shuttle vector, pAd (GenBank U62024) at SalI and NotI sites. Next, Ad5.SARS-CoV-2-S1N (Ad5.S1N) was created by loxP homologous recombination (Fig. 1A). To detect SARS-CoV-2-S1 expression driven by the generated Adenoviral candidate, the serum-free supernatants from A549 cells infected with Ad5.S1N were characterized by SDS-PAGE and western blot analysis. The recombinant SARS-CoV-2-S1N proteins (Ad5.S1N infected cells) were recognized by the polyclonal S1 and N antibody at the expected glycosylated monomer molecular weights of about 150 kDa (Fig. 1B and C).
Figure 1. Adenoviral-vectored SARS-CoV-2-S1N vaccine. (A) A shuttle vector carrying the codon-optimized SARS-CoV-2-S1 gene encoding N-terminal 1–661 along with full Nucleoprotein was designed as shown in the diagram. The vector was used to generate recombinant type 5 replication-deficient adenoviruses (Ad5) by homologous recombination with the adenoviral genomic DNA, shown by the BioRender illustration of Ad5.SARS-CoV-2-S1N. ITR, inverted terminal repeat. (B) Detection of the SARS-CoV-2-S1N fusion protein by western blot with the supernatant of A549 cells infected with Ad5.SARS-CoV-2-S1N (Ad5.S1N) using S1 SARS-CoV-2 rabbit polyclonal antibody (lane 1). As a positive control, supernatant of A549 cells infected with Ad5.SARS-CoV-2.S1 (Ad5.S1) was loaded (lane 2). As a negative control, supernatant of A549 cells infected with an empty vector (Ad/Psi1) was loaded (lane 3). (C) Detection of the SARS-CoV-2-S1N fusion protein by western blot with the supernatant of A549 cells infected with Ad5.SARS-CoV-2.S1N (Ad5.S1N) using N SARS-CoV-2 rabbit polyclonal antibody (lane 1). As a negative control, supernatant of A549 cells infected with Ad5.SARS-CoV-2.S1 (Ad5.S1) was loaded (lane 2). As a negative control, supernatant of A549 cells infected with an empty vector (Ad/Psi1) was also loaded (lane 3). The supernatants were resolved on SDS-10% polyacrylamide gel after being boiled in 2% SDS sample buffer with β-ME.

Single-shot immunogenicity of adenoviral SARS-CoV-2 S1N vaccine

To evaluate the impact of including the N protein of SARS-CoV-2 in vaccine formulation through a S1N fusion protein, we first compared the immunogenicity of Ad5.SARS-CoV-2-S1N (Ad5.S1N) with our previously published Ad5.SARS-CoV-2-S1 (Ad5.S1), which expresses S1 alone [34]. We determined S1-specific IgG, IgG1, and IgG2a endpoint titers in the sera of vaccinated BALB/cJ mice (either via I.N. delivery or S.C. injection) and control mice (Ad/Psi1 immunized groups). Serum samples, collected from mice at the timepoints indicated, were serially diluted to determine SARS-CoV-2-S1-specific IgG, IgG1, and IgG2a endpoint titers for each immunization group using ELISA (Fig. 2). Results suggest that both Ad5.S1 and Ad5.S1N resulted in comparable S1-specific IgG, IgG1, and IgG2a endpoint titers (Fig. 2). S.C. injection of Ad5.S1 and Ad5.S1N resulted in significantly increased S1-specific IgG endpoint titers as early as 2 weeks after a single vaccination, compared to the mock vaccinated group (Fig. 2A, p < 0.05, Kruskal-Wallis test, followed by Dunn’s multiple comparisons). I.N. Ad5.S1 and Ad5.S1N SARS-CoV-2-S1-specific IgG endpoint titer increased to comparable levels of S.C. injection by week 3 and were sustained through week 8 (Fig. 2A). Both Ad5.S1 and Ad5.S1N, regardless of immunization delivery route, resulted in similar IgG1 and IgG2a endpoint titers indicating a balanced Th1/Th2 response (Fig. 2B). To evaluate the functional quality of vaccine-generated antigen-specific antibodies, we used a microneutralization assay (NT90) to test the ability of sera from immunized mice to neutralize the infectivity of SARS-CoV-2. Sera, collected from all mice 6 and 8 weeks after vaccination, were tested for the presence of SARS-CoV-2-specific neutralizing antibodies (Fig. 2C). As expected, there was no detected neutralizing antibody response in sera of Ad/Psi1 immunized mice. Neutralizing antibodies were detected in Ad5.S1 and Ad5.S1N vaccinated mice (for both I.N. and S.C. delivery routes) at week 6. Neutralizing antibody response for I.N. delivery was greater in magnitude for both Ad5.S1 and Ad5.S1N, when compared to S.C. injection, with S.C. injected mice having low to undetectable neutralizing antibodies by week 8 (Fig. 2C). Next, we evaluated the antigen-specific cellular immune response induced by the single immunization. We investigated S1- and N-specific cellular immunity in mice after vaccination by quantifying IFN-γ+ CD8+ and CD4+ T-cell responses through intracellular cytokine staining (ICS) and flow cytometry. Results suggest that I.N. delivery of either Ad5.S1 or Ad5.S1N did not induce increased systemic S1-specific or N-specific CD8+ T-cell immunity, when compared to I.N. Ad/Psi1 control groups (Fig. 3A). However, S.C. vaccination induced increased systemic S1-specific IFN-γ+ CD8+ T-cell responses for both Ad5.S1 and Ad5.S1N. S.C. vaccination of Ad5.S1 and Ad5.S1N resulted in significantly increased S1-specific IFN-γ+ CD8+ T-cell response when compared to both
Figure 2. Antigen-specific antibody responses in mice immunized with adenoviral-vectored SARS-CoV-2-S1N vaccine. BALB/c mice (n = 5 mice per groups) were immunized intranasally (IN) or subcutaneously (SC) with $5 \times 10^{10}$ v.p. of Ad5.SARS-CoV-2-S1N (Ad5.S1N), Ad5.SARS-CoV-2-S1 (Ad5.S1), or empty Ad5 vector as negative control (Ad5/Psi1). On weeks 2, 4, 6, and 8 after vaccination, the sera from mice were collected, serially diluted (200×), and tested for the presence of SARS-CoV-2-S1-specific (A) IgG and (B) IgG1 & IgG2 antibody levels at the indicated time points by ELISA. (C) Serum titers that resulted in a 90% reduction in SARS-CoV-2 viral plaques (NT90) compared to the virus control are reported at 6 and 8 weeks after immunization, respectively, and bars represent geometric means. No neutralizing antibodies were detected in serum Ad5/Psi1 control group. Significance was determined by Kruskal-Wallis test followed by Dunn’s multiple comparisons ($p < 0.05$). Horizontal solid lines represent geometric mean antibody titers. Horizontal dotted lines represent minimum and maximum dilutions. Results are from a single animal experiment. (N = 5 mice per group). ELISA experiments were conducted twice while neutralizing antibody experiments were conducted once.

I.N. Ad5/Psi1 and S.C. Ad5/Psi1 (Fig. 3A, $p < 0.05$, one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons). S1-specific IFN-γ+ CD8+ T-cell response for S.C. vaccinated Ad5.S1N mice were significantly higher than in S.C. vaccinated Ad5.S1 mice (Fig. 3A, $p < 0.05$, one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons). However, S.C. vaccinated Ad5.S1N mice did not have significantly higher N-specific IFN-γ+ CD8+ T-cell response when compared to controls (Fig. 3B, $p > 0.05$, one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons). There was no significant increase in S1-specific or N-specific IFN-γ+ CD4+ T-cell response in vaccinated groups when compared to controls (Fig. 3B, $p > 0.05$, one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons). In sum, these finding indicate that a single vaccination with Ad5.S1 or Ad5.S1N, via either S.C. injection or I.N. delivery, results in a robust S1-specific IgG response, with a balanced IgG1/IgG2a ratio. The choice of the route of vaccine administration (S.C. or I.N.) influences both SARS-CoV-2 neutralizing antibodies and S1-specific CD8+ T-cell responses. Most importantly, inclusion of the N protein, through Ad5.S1N, results in a significantly higher induction of S1-specific CD8+ T-cells when compared to Ad5.S1.

Immunogenicity of homologous and heterologous prime-boost vaccination strategy

To evaluate the ability to further increase neutralizing antibody and cellular immune response to vaccination with Ad5.S1N, we investigated prime-boost strategies leveraging homologous and heterologous strategies. Prime-boost vaccination strategies have been shown to increase the quantity, durability, and quality of the immune response to vaccination and have been employed for numerous types of vaccines [50, 51]. Figure 4A outlines the prime-boost vaccination strategies used. Homologous prime-boost of Ad5.S1N using differing vaccination routes (I.N. and S.C.) was done to circumvent Ad5 vector immunity induced by prime immunization, which has been shown to limit the effectiveness of Ad5 vectored vaccines [52, 53]. We also evaluated a heterologous prime-boost group that was primed S.C. with Ad5.S1N and boosted with 15 μg of
antibodies (\(p < 0.05\), one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons). Taken together, these findings indicated the choice of vaccine administration order (S.C. or I.N. with \(5 \times 10^9\) v.p. of Ad5.SARS-CoV-2-S1 (Ad5.S1), Ad5.SARS-CoV-2-S1N (Ad5.S1N), or Ad\(\Psi\)5. Ten days after vaccination, splenocytes were isolated and stimulated with SARS-CoV-2 S1 and SARS-CoV-2 Nucleoprotein PepTivator, followed by ICS and flow cytometry to identify SARS-CoV-2 S1 and Nucleoprotein-specific T cells (see Supporting Information for complete gating strategy). (A) Frequencies of SARS-CoV-2 S1 and Nucleoprotein-specific CD8^+ IFN-\(\gamma\)^+ T cells were significantly higher when compared to controls (\(p < 0.05\), one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons). No N-specific CD8^+ T-cell immunity was detected for S.C. prime and I.N. boost of Ad5.S1N vaccinated mice. However, I.N. prime and S.C. boost of Ad5.S1N resulted in systemic S1-specific CD8^+ T-cell immunity with S1-specific CD8^+ T-cell immunity being significantly higher when compared to empty vector control (Fig. 5A, \(p > 0.05\), one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons).). Neutralizing ability was robust with I.N. prime and S.C. boost of Ad5.S1N, as indicated by higher S1-specific IgG, IgG1, IgG2a, and neutralizing antibody response when compared to single immunization alone. Although S.C. and I.N. boost of Ad5.S1N resulted in S1-specific CD8^+ T-cell immunity, this was not significant when compared to empty vector control (Fig. 5A, \(p > 0.05\), one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons).).
Figure 4. Homologous and heterologous prime-boost vaccination with Ad5.SARS-CoV-2-S1N (Ad5.SIN) using differing vaccination routes along with recombinant S1 protein (rS1). (A) Schematic layout of mice (N = 5 mice per group) vaccinations. Group 1 served as control with SC Ad5Ψ5 (1 × 10^10 v.p.) prime and IN AdΨ5 (1 × 10^10 v.p.) boost. Group 2 primed with SC Ad.S1N (1 × 10^10 v.p.) and IN Ad.S1N (1 × 10^10 v.p.) boost. Group 3 primed with IN Ad.S1N (1 × 10^10 v.p.) and SC Ad.S1N boost (1 × 10^10 v.p.). Group 4 primed with SC Ad.S1N (1 × 10^10 v.p.) and SC non-adjuvanted rS1 boost (15 μg). On weeks 3 and 6 after vaccination, the sera from mice were collected, serially diluted (200×), and tested for the presence of SARS-CoV-2-S1-specific (B) IgG antibody levels. (C) Week 6 sera were tested for the presence of IgG1 and IgG2 antibody levels. (D) Week 6 serum from immunized mice was tested for neutralizing antibodies using a plaque reduction neutralization test (PRNT) with three different SARS-CoV-2 strains from Wuhan, South Africa (Beta B.1.351), or Brazil (Gamma P.1). Neutralization of Wuhan strain represented by circle, neutralization of Beta B.1.351 represented by square, and neutralization of Gamma P.1 represented by triangle. Serum titers that resulted in a 90% reduction in SARS-CoV-2 viral plaques (NT90) compared to the virus control are reported at 6 weeks after immunization and bars represent geometric means. No neutralizing antibodies were detected in serum PBS control group (not shown). Significance was determined by Kruskal-Wallis test followed by Dunn’s multiple comparisons (*p < 0.05). Horizontal lines represent geometric mean antibody titers. Horizontal dotted lines represent minimum and maximum dilutions. Results are from a single animal experiment. (N = 5 mice per group). ELISA experiments were conducted twice while neutralizing antibody experiments were conducted once.

or I.N.) impacted S1-specific and N-specific CD8+ T-cell response.

Immunogenicity of heterologous prime-boost vaccination with Ad.S1N and variant specific recombinant S1 subunit protein

Due to the robust antibody response to S.C. Ad5.S1N prime and S.C. rS1 boost in Figure 5, we aimed to further compare the immunogenicity of recombinant monomeric S1 subunit vaccine formulation, at a higher dose of 45 μg, with Ad5.SIN. Figure 6A outlines the prime-boost vaccination strategies investigated with prime-boost of 45 μg rS1 WT, rS1 B.1.351, a combination of rS1 WT & rS1 B.1.351, and Ad5.SIN. A key advantage of harnessing heterologous prime-boost vaccination, with Ad5-vectored and recombinant subunit vaccines, is circumventing anti-Ad5 vector immunity induced by prime immunization [52, 53]. Due to not having to account for Ad5 vector immunity following prime immunization, along with the clinical familiarity with I.M. injection of vaccines, all mice were vaccinated intramuscularly.

Serum samples, collected from mice at the timepoints indicated, were used to determine S1-specific IgG, IgG1, and IgG2a endpoint titers for each immunization group using ELISA (Fig. 6). Heterologous Ad5.SIN prime with either WT rS1 or B.1.351 rS1 boost (Group 5 and Group 6) resulted in statistically different IgG at week 3 when compared to PBS vaccinated group (Fig. 6B, p < 0.05, Kruskal-Wallis test, followed by Dunn’s multiple comparisons). Groups vaccinated with rS1 protein, both WT and B.1.351 (Group 1 through Group 4), regardless of heterologous or homologous prime-boost, resulted in lower IgG endpoint titers that were not statistically different from control group at week 3 and, in some cases, significantly lower than Group 5 and Group 6 at week 5 and week 7 (Fig. 6B, p < 0.05, Kruskal-Wallis test, followed by Dunn’s multiple comparisons). Interestingly, mice vaccinated with
monomeric rS1 proteins (Group 1 through Group 4) showed a skew towards a IgG1 dominant response rather than the balanced IgG1 and IgG2a response in Ad5.S1N primed groups (Group 5 and Group 6) (Fig. 6C). To evaluate the functional quality of vaccine-generated antigen-specific antibodies, we used a microneutralization assay (NT90) to test the ability of sera from immunized mice to neutralize the infectivity of SARS-CoV-2. The ability of sera to neutralize Beta (B.1.351) and Gamma (P.1) variants was also investigated. Sera, collected from all mice at 7 weeks after prime vaccination, were tested for the presence of SARS-CoV-2-specific neutralizing antibodies (Fig. 7). Neutralizing antibodies were detected against WT, Beta, and Gamma, albeit relatively low, for monomeric rS1 vaccinated groups (Group 1 through Group 4) (Fig. 7). However, Ad5.S1N prime & rS1 WT boost (Group 5) and Ad5.S1N prime & rS1 B.1.351 boost (Group 6) resulted in the greatest amount of neutralizing capacity, which was not diminished against Beta (B.1.351) or Gamma (P.1). Due to the robust humoral response elicited by Group 5 and Group 6, along with the importance of long-lasting humoral response for protection against SARS-CoV-2 infection, mice were bled monthly, and on week 29 Group 1, Group 2, Group 5, and Group 6 were sacrificed to investigate the long-lived S1-specific and N-specific antibody-forming cells in the bone marrow (Fig. 8). As expected, PBS vaccinated mice did not induce any S1-specific or N-specific antibody-producing plasma cells in the bone marrow (Fig. 8). Group 1, Group 2, Group 5, and Group 6 had S1-specific IgG secreting spots, with Group 5 and Group 6 having significantly higher number of spots than PBS vaccinated mice (Fig. 8A, p < 0.05, Kruskal-Wallis test, followed by Dunn’s multiple comparisons). Indeed, only Group 5 and Group 6 had N-specific IgG secreting spots with a significant difference from PBS, Group 1, and Group 2 mice (Fig. 8B, p < 0.05, Kruskal-Wallis test, followed by Dunn’s multiple comparisons).

DISCUSSION

More immunization programs against SARS-CoV-2 are urgently needed to battle global vaccine inequity and new viral variants. Our study presents the development, and analysis in mice, of an Ad-based COVID vaccine incorporating novel antigen design (Ad5.SARS-CoV-2-S1N). Currently approved Ad-based SARS-CoV-2 vaccines, such as Oxford-AstraZenca, Janssen, CansinoBio, and Sputnik V COVID-19 vaccines, encode for full-length SARS-CoV-2 spike protein and are administered intramuscularly. Our vaccine encodes the gene for SARS-CoV-2-S1 subunit and SARS-CoV-2 N protein through a S1N fusion protein delivered in multiple administration routes (S.C., I.N., and I.M.). This study also investigates novel prime-boost immunization strategies leveraging subunit recombinant proteins that are relatively thermostable [61–63]. Further improvements could be achieved harnessing intracutaneous vaccination with microneedle arrays, which have been shown to deliver a wide range of recombinant DNA or protein vaccines [33, 64–66].

Our studies suggest that a single vaccination of BALB/c mice via either I.N. or S.C. delivery of 5 × 10^10 v.p. Ad5.SARS-CoV-2-S1N was capable of inducing antigen-specific IgG, Ig isotype switch, and a moderate neutralizing antibody response. We also show that Ad5.SARS-CoV-2-S1N shows a similar S1-specific antibody response, and
Figure 6. Homologous and heterologous intramuscular prime-boost vaccination with variant-specific recombinant S1 proteins (rS1) and Ad5.SARS-CoV-2-S1N (Ad5.S1N). BALB/c mice (n = 5 mice per groups) were immunized and boosted intramuscularly with 45 μg of Wuhan rS1 (rS1 WT), South Africa rS1 (rS1 B.1.351), mixture of Wuhan rS1 and South Africa rS1 (rS1 WT+B.1.351), or 1 × 10^{10} v.p. of Ad5.SARS-CoV-2-S1N (Ad5.S1N), while mice were immunized intramuscularly with PBS as a negative control. (A) Schematic layout of mice (N = 5 mice per group) vaccinations. Group 1 prime and homologous boost 15 μg rS1 WT. Group 2 prime and homologous boost 15 μg rS1 B.1.351. Group 3 prime and homologous boost 15 μg rS1 WT+B.1.351. Group 4 prime 15 μg rS1 WT and heterologous boost 15 μg rS1 B.1.351. Group 5 prime 1 × 10^{10} v.p. Ad5.S1N and heterologous boost 15 μg rS1 WT. Group 6 prime 1 × 10^{10} v.p. Ad5.S1N and heterologous boost 15 μg rS1 B.1.351. Antigen-specific antibody responses in mice immunized. On weeks 3, 5, and 7 after vaccination, the sera from mice were collected, serially diluted (200×), and tested for the presence of SARS-CoV-2-S1-specific (B) IgG and (C) IgG1 and IgG2a antibody levels at the indicated time points by ELISA. Significance was determined by Kruskal-Wallis test followed by Dunn’s multiple comparisons (p < 0.05). Horizontal lines represent geometric mean antibody titers. Horizontal dotted lines represent minimum and maximum dilutions. Results are from a single animal experiment. (N = 5 mice per group). ELISA experiments were conducted twice while neutralizing antibody experiments were conducted once.

neutralizing response, to Ad5.SARS-CoV-2-S1. We believe this is important as a concern with including proteins outside of the SARS-CoV-2 S protein is that it will decrease the antibody response against S. We show that this is not the case and that inclusion of N, through S1N fusion antigen, does not reduce S1-specific antibody responses. S.C. delivery of Ad5.SAR-CoV-2-S1N induced a significantly increased S1-specific T cell response, when compared to S.C. delivery of AdΨ5 and S.C. delivery of Ad5.SARS-CoV-2-S1. We hypothesize that this increased S1-specific T-cell response to Ad5.SARS-CoV-2-S1N may be due to the inclusion of N-derived T-cell epitopes, in the fusion protein, aiding in processing and presentation of S1 by MHC molecules, especially for presentation to CD8 T cells; however, this needs to be further elucidated through mechanism studies [67, 68]. We also illustrate that this immunogenicity can be improved by homologous prime-boost strategies, using either S.C. or I.N. delivery. Particularly immunogenicity can further be improved through heterologous prime-boost, with traditional I.M. injection, using subunit recombinant S1 protein. Priming with low dose (1 × 10^{10} v.p.) of Ad5.S1N and boosting with either WT recombinant rS1 or B.1.351 recombinant rS1 induced a robust neutralizing response, which was sustained against immune evasive variants, and a long-lived antibody-forming cell response in the bone marrow 29 weeks post vaccination. Interestingly, boosting with B.1.351 recombinant rS1 did not increase the neutralizing response to SARS-CoV-2 Beta variant virus when compared to boosting with WT recombinant rS1. The results are promising and support the use of a heterologous prime-boost immunization routine using Ad5.S1N and subunit recombinant S1 protein to induce antigen-specific humoral and cellular responses, leading to generation of long-lived plasma cells, and a potent CD8+ T-cell response. For the subunit recombinant S1 protein antigens, it is important to note that these are non-adjuvanted monomeric S1 proteins, which may explain the relatively poor neutralization breadth seen after prime-boost vaccination in Figure 7 for Groups 1–4. Our results suggest that monomeric non-adjuvanted subunit recombinant S1
The coding sequence for SARS-CoV-2 S1 amino acids 1–661 of full length from BetaCoV/Wuhan/IPBCAMS-WH-05/2020 (GISAID accession id. EPI_ISL_403928) flanked not only help by introducing more conserved regions of SARS-CoV-2 to the immune system, potentially allowing for resistance against emerging variants, but will also assist in viral clearance. This is particularly important in the context of long COVID and in populations that are at high risk of SARS-CoV-2 morbidity and mortality where the T-cell response has been shown to play an important role [70–74]. While previous clinical translation of Ad vaccines has been hampered by pre-existing immunity against the Ad viral capsid, CanSino Convidicea Vaccine (Ad5-nCoV), encoding for the full S protein, was able to overcome pre-existing vector immunity while using intramuscular immunization [47, 48]. Immunization with Ad-based vaccines, such as Ad5.S1N, could be an important tool to combat COVID-19 global vaccine inequality and the emergence of immune evasive SARS-CoV-2 variants. These finding concerning the immunogenicity of the S1N fusion antigen also adds knowledge to general COVID-19 vaccine approaches as S1N can be expressed through other vaccine vectors, such as mRNA or DNA technologies.

BALB/cJ mice have historically been used to investigate numerous different coronavirus vaccines and represent a reliable model for testing of immunogenicity of Ad5.SARS-CoV-2-S1N [33, 35, 75]. However, it is difficult to extrapolate our results in BALB/cJ mice to potential immunogenicity in humans. Particularly, our findings on the potency of S1- and N-specific T-cell response to Ad5.SARS-CoV-2-S1N vaccination may not directly translate to responses in humans due to the differences in human leukocyte antigen (HLA) and mouse major histocompatibility complex (MHC). The difference in HLA and MHC may explain the lack of N-specific T-cell response after vaccination, as N-derived epitopes may be less able to bind to mouse MHC than S1-derived epitopes. The lack of CD4 T-cell responses may also be explained by the model organism, BALB/cJ mice, which have been shown to have an abrogated CD4 T-cell response when compared to C57BL/6 mice [76]. To this effect, future studies will use more translatable animal models such as hACE2 mice and rhesus macaques. Our future studies will also include animal challenge models with live SARS-CoV-2 virus to investigate protection against infection and death. Along with these studies, we will also harvest axillary and cervical lymph nodes to investigate the specific kinetics and location of T-cell immunity post intramuscular vaccination.

Taken together, this study illustrates the potential of Ad5.SARS-CoV-2-S1N as it induces significant antigen-specific humoral and cellular immune responses against SARS-CoV-2. Particularly, heterologous prime-boost vaccine with low dose Ad5.SARS-CoV-2-S1N along with subunit recombinant S1 protein have the potential to induce a very effective virus-specific immune response against COVID-19 and emerging SARS-CoV-2 variants.
Figure 8. Analysis of long-term persistent antibody forming responses in the bone marrow of immunized mice. Mice were immunized as follows: Group 1 prime and homologous boost 45 \( \mu \)g rS1 WT. Group 2 prime and homologous boost 45 \( \mu \)g rS1 B.1.351. Group 5 prime 1 \( \times \) 10\(^{10} \) v.p. Ad5.S1N and heterologous boost 45 \( \mu \)g rS1 WT. Group 6 prime 1 \( \times \) 10\(^{10} \) v.p. Ad5.S1N and heterologous boost 45 \( \mu \)g rS1 B.1.351. Mice injected with PBS only served as negative controls. 29 weeks after immunization, S1-specific and N-specific antibody-forming cells in the bone marrow of mice were analyzed using ELISpot. (A) Quantification of SARS-CoV-2 S1-specific antibody forming cells in the bone marrow of immunized mice. (B) Quantification of SARS-CoV-2 N-specific antibody forming cells in the bone marrow of immunized mice. Data are from a single experiment (\( n = 5 \) per group). This experiment was conducted once.

with SalI and BamH I-6H-Not I was codon-optimized using the UpGene algorithm for optimal expression in mammalian cells and synthesized (GenScript) ref. 2020 EBioM [77]. pAd/SARS-CoV-2-S1 was then created by subcloning the codon-optimized SARS-CoV-2-S1 gene into the shuttle vector, pAdlox (GenBank U62024), at Sal I/Not I sites. The coding sequence of N (GenBank NC_045512) having Sac I & Sal I in 5' end and Not I & Apa I in 3' end was synthesized and cloned in Sac I/ApaI sites in pCMV-3Tag-4A generated in pCMV3/SARS-CoV-2-N (GenScript). For the construction of pAd/SARS-CoV-2-S1N, BamH I-6H-Not I of pAd/SARS-CoV-2-S1 was replaced with Nucleoprotein gene digested with BamH I and Not I after amplified with NP-S (5'-GACGGATCCATGTCTGATAATGGACCCC-3') and T7 (5'-TAATACGACTCACTATAGGG-3') primers from pCMV3/SARS-CoV-2-NP. Subsequently, replication-deficient human recombinant serotype 5 adenovirus vector (Ad5.SARS-CoV-2-S1N) was generated by loxP homologous recombination and purified [35, 78, 79].

Construction of recombinant protein expressing vectors

The coding sequence for SARS-CoV-2-S1 amino acids 1–661 of full length from BetaCoV/Wuhan/IPBCAMS-WH-05/2020 (GISAID accession id. EPI_ISL_403928) having C-terminal tag known as ‘C-tag’, composed of the four amino acids (aa), glutamic acid–proline–glutamic acid–alanine (E-P-E-A) flanked with SalI and NotI was codon-optimized using the UpGene algorithm for optimal expression in mammalian cells and synthesized (GenScript) [77]. The construct also contained a Kozak sequence (GCC ACC) at the 5’ end. For B.1.351 variant, SARS-CoV-2-S1 mutated (Del144; K417N; E484K; N501Y; A570D; D614G) was synthesized based on above codon-optimized SARS-CoV-2-S1 from Wuhan. pAd/SARS-CoV-2-S1WU and pAd/SARS-CoV-2-SAS1SA were then created by subcloning the codon-optimized SARS-CoV-2-S1 inserts into the shuttle vector, pAdlox (GenBank U62024), at SalI/NotI sites. The plasmid constructs were confirmed by DNA sequencing.

Transient production of recombinant proteins in Expi293 cells

pAd/SARS-CoV-2-S1WU and pAd/SARS-CoV-2-SAS1SA were amplified and purified using ZymoPURE II plasmid maxiprep kit (Zymo Research). For Expi293 cell transfection, we used ExpiFectamine™ 293 Transfection Kit (ThermoFisher) and followed the manufacturer’s instructions. Cells were seeded 3.0 \( \times \) 10^6 cells/ml 1 day before transfection and grown to 4.5–5.5 \( \times \) 10^6 cells/ml. One microgram of DNA and ExpiFectamine mixtures per 1 ml culture were combined and incubated for 15 minutes before adding into 3.0 \( \times \) 10^6 cells/ml culture. At 20 hours post-transfection, enhancer mixture was added, and culture was shifted to 32°C. The supernatants were harvested 5 days post transfection and clarified by centrifugation to remove cells, filtered through 0.8 \( \mu \)m, 0.45 \( \mu \)m, and 0.22 \( \mu \)m filters, and either subjected to further purification or stored at 4°C before purification.
Purification of recombinant proteins

The recombinant proteins named rS1WT (Wuhan) and rS1 B1.351 were purified using a CaptureSelect™ C-tagXL Affinity Matrix prepacked column (ThermoFisher) and followed the manufacturer’s guidelines [80]. Briefly, the C-tagXL column was conditioned with 10 column volumes (CV) of equilibrate/wash buffer (20 mM Tris, pH 7.4) before sample application. Supernatant was adjusted to 20 mM Tris with 200 mM Tris (pH 7.4) before being loaded onto a 5-mL prepacked column per the manufacturer’s instructions at 5 mL/min rate. The column was then washed by alternating with 10 CV of equilibrate/wash buffer, 10 CV of strong wash buffer (20 mM Tris, 1 M NaCl, 0.05% Tween-20, pH 7.4), and 5 CV of equilibrate/wash buffer. The recombinant proteins were eluted from the column by using elution buffer (20 mM Tris, 2 M MgCl2, pH 7.4). The eluted solution was concentrated and desalted with preservative buffer (PBS) in an Amicon Ultra centrifugal filter devices with a 50 000 molecular weight cutoff (Millipore). The concentrations of the purified recombinant proteins were determined by the Bradford assay using bovine serum albumin (BSA) as a protein standard, aliquoted, and stored at −80°C until use.

SDS-PAGE and western blot

To evaluate the infectivity of the constructed recombinant adenoviruses, A549 (human lung adenocarcinoma epithelial cell line) cells were transduced with a multiplicity of infection of 7.5 (MOI = 7.5) of Ad5.SARS-CoV-2-S1N, Ad5.SARS-CoV-2-S1, and empty vector control (AdΨ5). At 48 hours after infection, cell supernatant was collected. The supernatants of A549 cells transduced with Ad5.SARS-CoV-2-S1N, Ad5.SARS-CoV-2-S1, and AdΨ5 were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot. Briefly, after the supernatants were boiled in Laemmli sample application. Supernatant was adjusted to 20 mM Tris with 200 mM Tris (pH 7.4) before being loaded onto a 5-mL prepacked column per the manufacturer’s instructions at 5 mL/min rate. The column was then washed by alternating with 10 CV of equilibrate/wash buffer, 10 CV of strong wash buffer (20 mM Tris, 1 M NaCl, 0.05% Tween-20, pH 7.4), and 5 CV of equilibrate/wash buffer. The recombinant proteins were eluted from the column by using elution buffer (20 mM Tris, 2 M MgCl2, pH 7.4). The eluted solution was concentrated and desalted with preservative buffer (PBS) in an Amicon Ultra centrifugal filter devices with a 50 000 molecular weight cutoff (Millipore). The concentrations of the purified recombinant proteins were determined by the Bradford assay using bovine serum albumin (BSA) as a protein standard, aliquoted, and stored at −80°C until use.

Animals and immunization

For single immunization experiment, BALB/cJ mice (n = 5 animals per group in each independent experiment) were vaccinated by either I.N. delivery or S.C. injection of 5 × 10^10 viral particles (v.p.) of AdΨ5 (a null Ad5 vector negative control), Ad5.SARS-CoV-2-S1, or by Ad5.SARS-CoV-2-S1N. Mice were bled from retro-orbital vein at weeks 0, 2, 4, 6, and 8 after immunization, and the obtained serum samples were diluted and used to evaluate S1-specific antibodies by enzyme-linked immunosorbent assay (ELISA). Serum samples obtained on weeks 8 and 12 after vaccination were also for microneutralization (NT) assay. For homologous and heterologous prime-boost immunization experiment, BALB/cJ mice (n = 5 animals per group in each independent experiment) were primed or boosted by either I.N. delivery or S.C. injection of 1 × 10^8 viral particles (v.p.) of AdΨ5 (a null Ad5 vector negative control), Ad5.SARS-CoV-2-S1N, or by 15 μg of non-adjuvanted subunit recombinant wild-type S1 monomeric protein. Mice were bled from retro-orbital vein at weeks 3 and 6 after immunization, and the obtained serum samples were diluted and used to evaluate S1-specific antibodies by enzyme-linked immunosorbent assay (ELISA). Serum samples obtained on week 6 after vaccination were also used for microneutralization (NT) assay. For heterologous prime-boost immunization experiment, BALB/cJ mice (n = 5 animals per group in each independent) were primed or boosted intramuscularly with 45 μg of rS1 WT and/or rS1 B1.351, or by Ad5.SARS-CoV-2-S1N. Mice were bled from retro-orbital vein at weeks 3, 5, and 6 after immunization, and the obtained serum samples were diluted and used to evaluate S1-specific antibodies by enzyme-linked immunosorbent assay (ELISA). Serum samples obtained on week 6 after vaccination were also used for microneutralization (NT) assay. Mice were maintained under specific pathogen-free conditions at the University of Pittsburgh, and all experiments were conducted in accordance with animal use guidelines and protocols approved by the University of Pittsburgh’s Institutional Animal Care and Use (IACUC) Committee.

ELISA

Sera from all mice were collected prior to immunization (week 0) and at weeks indicated after immunization and evaluated for SARS-CoV-2-S1-specific IgG, IgG1, and IgG2a antibodies using ELISA [34]. Briefly, ELISA plates were coated with 200 ng of recombinant SARS-CoV-2-S1 protein (Sino Biological) per well overnight at 4°C in carbonate coating buffer (pH 9.5) and then blocked with PBS-T and 2% BSA for 1 hour. Mouse sera were serially diluted in PBS-T with 1% BSA and incubated overnight. After the plates were washed, anti-mouse IgG-herosaderish peroxidase (HRP) (1:10 000, Santa Cruz) was added to each well and incubated for 1 hour. The plates were washed three times, developed with 3,3′,5′-tetramethylbenzidine, and the reaction was stopped. Next, absorbance was determined at 450 nm using a plate reader. For IgG1 and IgG2a ELISAs, mouse sera were diluted in PBS-T with 1% BSA and incubated overnight. After the plates were washed, biotin-conjugated IgG1 and IgG2a (1:1000, eBioscience) and biotin horseradish peroxidase (Av-HRP) (1:50 000, Vector Laboratories) were added to each well and incubated for 1 hour. The plates were washed three times and developed with 3,3′,5′-tetramethylbenzidine,

Antibody Therapeutics, 2022 187
the reaction was stopped, and absorbance at 450 nm was determined using a plate reader.

Flow cytometry analysis for cellular immune responses

Antigen-specific T-cell responses in the spleen of BALB/cJ mice immunized as described above were analyzed after immunization by flow cytometry, adhering to the recently published guidelines [81]. Briefly, spleens were mashed and underwent erythrocyte lysis using the Mouse Erythrocyte Lysing Kit (R&D Systems, WL200); remaining cells were used for cellular immune response analysis. Isolated splenocytes from vaccinated and PBS control mice were stimulated with PepTivator SARS-CoV-2-S1 (a pool of S1 MHC class I– and MHC class II– restricted peptides) or SARS-CoV-2-N (a pool of N MHC class I– and MHC class II– restricted peptides) overnight in the presence of protein transport inhibitors (Golgi Stop) for 10 min at 4°C. Stained with surface marker antibody (Ab) stain overnight for 20 min at 4°C. Surface Abs were used as follows: anti-CD45 (30-F11, BV480, BD Biosciences), anti-TCRb (Alexa Fluor® 700, BD Biosciences), anti-CD4 (GK1.5, BUV650, BioLegend), and anti-CD8a (53-6.7, BVU570, BioLegend). For dead cell exclusion, cells were stained with Zombie NIR Fixable Viability dye (BioLegend). For dead cell exclusion, cells were stained with Zombie NIR Fixable Viability dye (BioLegend) for 10 min at 4°C and washed in FACS buffer. ICS was performed on surface Ab-stained cells by first fixing and permeabilizing cells using the FoxP3 Transcription Factor Staining Buffer kit (eBioscience, 00-5523-00) following manufacturer’s instructions. Intracellular staining with anti-IFN-γ Ab (XMG1.2, BV605, BioLegend) for 30 min at 4°C was performed. Samples were run on an Aurora (Cytek) flow cytometer and analyzed with FlowJo v10 software (BD Biosciences). Live, antigen-specific, IFN-γ producing CD8+ and CD4+ T cells were identified according to the gating strategy in Supplementary Figure 1. Results for positive and negative controls are also available in Supplementary Figure 2.

SARS-CoV-2 microneutralization assay

Neutralizing antibody (NT-Ab) titers against SARS-CoV2 were defined according to the following protocol [82, 83]. Briefly, 50 μl of sample from each mouse, in different dilutions, were added in two wells of a flat bottom tissue culture microtiter plate (COSTAR, Corning Incorporated, NY 14831, USA), mixed with an equal volume of 100 TCID50 of a SARS-CoV2 wild-type, Beta, or Gamma variant isolated from symptomatic patients, previously titrated and incubated at 33°C in 5% CO2. All dilutions were made in EMEM (Eagle's Minimum Essential Medium) with addition of 1% penicillin, streptomycin, and glutamine and 5 γ/ml of trypsin. After 1 hour incubation at 33°C 5% CO2, 3 × 10^6 VERO E6 cells [VERO C1008 (Vero 76, clone E6, Vero E6); ATCC® CRL-1586TM] were added to each well. After 72 hours of incubation at 33°C, 5% CO2 wells were stained with Gram’s crystal violet solution (Merck KGaA, 64271 Darmstadt, Germany) plus 5% formaldehyde 40% m/v (Carlo ErbaSpA, Arese (MI), Italy) for 30 min. Microtiter plates were then washed in running water. Wells were scored to evaluate the degree of cytopathic effect (CPE) compared to the virus control. Blue staining of wells indicated the presence of neutralizing antibodies. Neutralizing titer was the maximum dilution with the reduction of 90% of CPE. A positive titer was equal or greater than 1:5. Sera from mice before vaccine administration were always included in microneutralization (NT) assay as a negative control.

ELISPOT for antibody forming cells

The frequency of SARS-CoV-2-specific antibody producing cells in the bone marrow of mice was determined by ELISPOT assay 29 weeks after immunization using our established and previously published methods [84, 85]. Briefly, 4-HBX plates were coated as described for ELISA assays, and non-specific binding was blocked with RPMI media containing 5% FCS. Dilution series of cells of each individual bone marrow sample was plated in triplicates and incubated at 37°C for 5 hours. Secondary Ab (anti-mIgG- alkaline phosphatase; Southern Biotech) was detected using 5-bromo-4-chloro-3-indolyl phosphate substrate (BCIP; Southern Biotech) in 0.5% low melting agarose (Fisher Scientific). Spots were counted using a binocular on a dissecting microscope and the detected numbers of IgG anti-SARS-CoV-2-S1 and anti-SARS-CoV-2-N antibody-forming cells were calculated per million bone marrow cells.

Statistical analysis

Statistical analyses were performed using GraphPad Prism v9 (San Diego, CA). Antibody endpoint titers and neutralization data were analyzed by Kruskal-Wallis test, followed by Dunn’s multiple comparisons. T-cell data were analyzed by one-way Welch’s ANOVA, followed by Dunnett’s T3 multiple comparisons. Significant differences are indicated by *p < 0.05. Comparisons with non-significant differences are not indicated.

Author contributions

Conceptualization: M.S.K., E.K., and A.G. Data curation: M.S.K., E.K., A.M., F.J.W., E.P., I.C., F.B., M.M., and A.G. Formal analysis: M.S.K., E.K., and A.G. Investigation: M.S.K., E.K., A.M., F.J.W., S.H., T.W.K., B.L.H., E.P., and I.C. Methodology: M.S.K., E.K., and A.G. Resources: M.M. and A.G. Visualization: M.S.K., E.K., and A.G. Writing—original draft preparation: M.S.K., E.K., A.M., F.J.W., S.H., T.W.K., B.L.H., E.P., I.C., F.B., M.M., and A.G.

ACKNOWLEDGEMENTS

Figures 1A, 4A, and 6A were created using Biorender.com.
SUPPLEMENTARY DATA
Supplementary Data are available at ABT Online

FUNDING
A.G. is funded by National Institutes of Health grants (UM1AI106701, R21-AI130180, U01-CA233085) and UPMC Enterprises (IPA 25565). M.M. is funded by National Institutes of Health/NIDDK grant (DK130897). These funding institutions had no role in the study design, data collection, data analysis, and interpretation of this publication.

CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the finding of this study are available from the corresponding author upon reasonable request.

ETHICS AND CONSENT STATEMENT
Patient consent was not required.

ANIMAL RESEARCH STATEMENT
Mice were maintained under specific pathogen-free conditions at the University of Pittsburgh, and all experiments were conducted in accordance with animal use guidelines and protocols approved by the University of Pittsburgh’s Institutional Animal Care and Use (IACUC) Committee. Experiments with animals were performed in accordance with local and national legal requirements such as AAALAC International and the United States Department of Agriculture.

REFERENCES
1. Lai, CC, Shih, TP, Ko, WC et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924.
2. Chakraborty, I, Maiti, P. COVID-19 outbreak: migration, effects on society, global environment and prevention. Sci Total Environ 2020; 728: 138882.
3. Haleem, A, Javid, M, Vaishya, R. Effects of COVID-19 pandemic in daily life. Current Medicine Research and Practice 2020; 10: 78–9.
4. Ada, G. Overview of vaccines and vaccination. Mol Biotechnol 2005; 29: 255–72.
5. Schuchat, A. Human vaccines and their importance to public health. Procedia Vaccinol 2011; 5: 120–6.
6. Rodrigues, CMC, Plotkin, SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol 2020; 11.
7. Ehreth, J. The global value of vaccination. Vaccine 2003; 21: 596–600.
8. Milken Institute. COVID-19 treatment and vaccine tracker. 2020. https://covid-19tracker.milkeninstitute.org/ (7 June 2021, last accessed).
9. Kim, JH. SARS-CoV-2 vaccine development, access, and equity. J Exp Med 2020; 217.
10. Moghadas, SM, Vilches, TN, Zhang, K et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis 2021; 73(12): 2257–64. https://doi.org/10.1093/cid/ciaa079.
11. National Academies of Sciences, Engineering and Medicine. Ensuring Equity in COVID-19 Vaccine Allocation Globally. In: Gayle, H et al. (eds). Framework for Equitable Allocation of COVID-19 Vaccine. Washington, DC: The National Academies Press, 2020; 272.
12. Jackson, LA, Anderson, EJ, Rouphael, NG et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. New Engl J Med 2020; 383: 1920–31.
13. Tatar, M, Shourekhalili, JM, Faraji, MR et al. International COVID-19 vaccine inequality amid the pandemic: perpetuating a global crisis? J Glob Health 2021; 11: 03086–6.
14. Juno, IA, Wheatley, AK. Boosting immunity to COVID-19 vaccines. Nat Med 2021; 27: 1874–75.
15. Shroff, RT, Chalasani, P, Wei, R et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 2021; 27: 2002–11.
16. Choi, A, Koch, M, Wu, K et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med 2021; 27: 2025–31.
17. Dyer, O. Covid-19: rich countries’ booster plans will impede global vaccination, experts say. BMJ 2021; 374: n2353.
18. Tao, K, Tzou, PL, Nouhin, J et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021; 22: 757–73.
19. Harvey, WT, Carabelli, AM, Jackson, B et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021; 19: 409–24.
20. Pulliam, JRC, Schalkwyk, CV, Govender, N et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022; 376(6593), eaab4947. https://doi.org/10.1126/science.abab4947.
21. He, X, Hong, W, Pan, X et al. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm 2021; 2: 838–45.
22. Schoeman, D, Fielding, BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16: 69.
23. Khan, S, Siddique, R, Sheereen, MA et al. Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options. J Clin Microbiol 2020; 58.
24. Tang, T, Bidon, M, Jaimes, JA et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res 2020; 178: 104792.
25. Li, X et al. Human coronaviruses: general features. Ref Module Biomed Sci 2019; B978-0-12-801238-3.957040-4.
26. Walls, AC, Park, YJ, Tortorici, MA et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181: 281–292.e6.
27. Yan, R, Zhang, Y, Li, Y et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444–8.
28. Jiang, S, Hillyer, C, Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol 2020; 41: 355–9.
29. García-Beltran, WF, Lam, EC, Astudillo, MG et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184: 476–488.e11.
30. Khoury, DS, Cromer, D, Reynaldi, A et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205–11.
31. Earle, KA, Ambrosino, DM, Fiore-Gartland, A et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021; 39: 4423–8.
32. Addetta, A, Crawford, KHD, Dingens, A et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol 2020; 58: e02107–20.
33. Kim, E, Erdos, G, Huang, S et al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine 2020; 55: 102743.
34. Kim, E, Weisel, FJ, Balmert, SC et al. A single subcutaneous or intranasal immunization with adenvirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. Eur J Immunol 2021; 51: 1774–84.
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. 

Lancet Infect Dis 2021; 21: 1212–3.

Guthmiller, JJ, Stovicek, O, Wang, J et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. 

MBio 2021; 12: e02940–20.

35. Kim, E, Okada, K, Kenninston, T et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. 

Vaccine 2014; 32: 5975–82.

36. Gao, W, Tamin, A, Solofli, A et al. Effects of a SARS-associated coronavirus vaccine in monkeys. 

Lancet 2003; 362: 1895–6.

37. Bai, Z, Cao, Y, Liu, W et al. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. 

Viruses 2021; 13.

38. Marra, MA, Jones, SJM, Astell, CR et al. The genome sequence of the SARS-associated coronavirus. 

Science 2003; 300: 1399–404.

39. Oliveira, SC, de Magalhães, Homan, EJ. Immunoinformatic analysis of SARS-CoV-2 nucleocapsid protein and identification of COVID-19 vaccine targets. 

Front Immunol 2020; 11.

40. Le Bert, N et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. 

Nature 2020; 584: 457–62.

41. Lineburg, KE, Grant, EJ, Swaminathan, S et al. CD8(+ ) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. 

Immunity 2021; 54: 1055–1065.e5.

42. Lee, E, Sandgren, K, Duette, G et al. Identification of SARS-CoV-2 nucleocapsid and spike T-cell epitopes for assessing T-cell immunity. 

J Virol 2021; 95: 13221.e1-13221.e26.

43. Gilbert, SC, Warinme, GM. Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology. 

Vaccine 2017; 35: 4461–4.

44. Van Kampen, KR et al. Safety and immunogenicity of adenovirus-vector nasal and epicutaneous influenza vaccines in humans. 

Vaccine 2005; 23: 1029–36.

45. Stanley, DA, Honko, AN, Asiedu, C et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. 

Immunity 2014; 40: 2116–9.

46. Mendonça, SA, Lorincz, R, Boucher, P et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. 

nvj Vaccines 2021; 6: 97.

47. Zhu, FC, Li, YH, Guan, XH et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. 

Lancet 2020; 395: 1845–54.

48. Zhu, FC, Guan, XH, Li, YH et al. Immunogenicity and safety of a recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. 

Lancet 2020; 396: 479–88.

49. Hernández-Bello, J, Morales-Núñez, JJ, Machado-Sulbarán, AC et al. Neutralizing antibodies against SARS-CoV-2, anti-Ad5 antibodies, and reactogenicity in response to Ad5-sCoV (CanSino biologics) vaccine in individuals with and without prior SARS-CoV-2. 

Vaccines (Basel) 2021; 9.

50. Kardani, K, Bolhassani, A, Shaibazi, S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. 

Vaccine 2016; 34: 413–23.

51. Palgen, J-L, Feraoun, Y, Dzangue-Tchoupou, G et al. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. 

Front Immunol 2021; 12.

52. Fausther-Bovendo, H, Kobinger, GP. Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what’s important? 

Hum Vaccin Immunother 2014; 10: 2875–84.

53. McCoy, K, Tatsis, N, Koroith-Schmitz, B et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. 

J Virol 2007; 81: 6594–604.

54. Sapkota, B, Saud, B, Shrestha, R et al. Heterologous prime–boost strategies for COVID-19 vaccines. 

J Travel Med 2021; 29.

55. Shaw, RH, Stuart, A, Greenland, M et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. 

The Lancet 2021; 397: 2093–46.

56. Tenbusch, M, Schumacher, S, Vogel, E et al. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. 

Lancet Infect Dis 2021; 21: 1212–3.
81. Cossarizza, A, Chang, HD, Radbruch, A et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol 2019; 49: 1457–973.
82. Percivalle, E, Cassaniti, I, Sarasini, A et al. West Nile or Usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors. Viruses 2020; 12: 157.
83. Percivalle, E, Cambie, G, Cassaniti, I et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill 2020; 25: 2001031.
84. Weisel, FJ, Zuccarino-Catania, GV, Chikina, M et al. A temporal switch in the germinal Center determines differential output of memory B and plasma cells. Immunity 2016; 44: 116–30.
85. Good-Jacobson, KL, Szumilas, CG, Chen, L et al. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 2010; 11: 535–42.